Growth factors and epithelial-stromal interactions in prostate cancer development

International Review of Cytology

Volumn 199, Issue , 2000, Pages 65-116

  Wong, Y C ^a   Wang, Y Z ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carcinogenesis growth factors; Epithelial stromal interactions; Prostate cancer; Tumorigenesis

Indexed keywords

EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL INTERACTION; DEVELOPMENT; EPITHELIUM; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STROMA;

EID: 0033918096     PISSN: 00747696     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0074-7696(00)99002-8     Document Type: Review

References (251)

1. Abu-Jawdeh, G. M., Faix, J. D., Niloff, J., Tognazzi, K., Manseau, E., Dvorak, H. F., and Brown, L. F. (1996). Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab. Invest. 74, 1105-1115.
2. Balbay, M. D., Pettaway, C. A., Kuniyasu, H., Inoue, K., Ramirez, E., Li, E., Fidler, I. J., and Dinney, C. P. (1999). Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor [In Process Citation]. Clin. Cancer Res. 5, 783-789.
3. Bao, L., Loda, M., Janmey, P. A., Stewart, R., Anand-Apte, B., and Zetter, B. R. (1996). Thymosin beta 15: A novel regulator of tumor cell motility upregulated in metastatic prostate cancer [see Comments]. Nat. Med. 2, 1322-1328.
4. Barrack, E. R. (1997). TGF beta in prostate cancer: A growth inhibitor that can enhance tumorigenicity. Prostate 31, 61-70.
5. Begun, F. P., Story, M. T., Hopp, K. A., Shapiro, E., and Lawson, R. K. (1995). Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates. J. Urol. 153, 839-843.
6. Bhatia-Gaur, R., Donjacour, A. A., Sciavolino, P. J., Kim, M., Desai, N., Young, P., Norton, C. R., Gridley, T., Cardiff, R. D., Cunha, G. R., Abate-Shen, C., and Shen, M. M. (1999). Roles for nkx3.1 in prostate development and cancer [in Process Citation]. Genes Dev. 13, 966-977.
7. Blaber, M., DiSalvo, J., and Thomas, K. A. (1996). X-ray crystal structure of human acidic fibroblast growth factor. Biochemistry 35, 2086-2094.
8. Bookstein, R., Shew, J. Y., Chen, P. L., Scully, P., and Lee, W. H. (1990). Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247, 712-715.
9. Bosman, F. T., de Bruine, A., Flohil, C., van der Wurff, A., ten Kate, J., and Dinjens, W. W. (1993). Epithelial-stromal interactions in colon cancer. Int. J. Dev. Biol. 37, 203-211.
10. Brooks, J. D., Bova, G. S., and Isaacs, W. B. (1995). Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 26, 35-39.
11. Brooks, J. D., Bova, G. S., Ewing, C. M., Piantadosi, S., Carter, B. S., Robinson, J. C., Epstein, J. I., and Isaacs, W. B. (1996). An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res. 56, 3814-3822.
12. Brown, L. F., Yeo, K. T., Berse, B., Morgentaler, A., Dvorak, H. F., and Rosen, S. (1995). Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen, J. Urol. 154, 576-579.
13. Bubendorf, L., Kononen, J., Koivisto, P., Schraml, P., Moch, H., Gasser, T. C., Willi, N., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. (1999). Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 59, 803-806.
14. Bussemakers, M. J., van Moorselaar, R. J., Giroldi, L. A., Ichikawa, T., Isaacs, J. T., Takeichi, M., Debruyne, F. M., and Schalken, J. A. (1992). Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res. 52, 2916-2922.
15. Chang, S. M., and Chung, L. W. (1989). Interaction between prostatic fibroblast and epithelial cells in culture: Role of androgen. Endocrinology 125, 2719-2727.
16. Cheifetz, S., Hernandez, H., Laiho, M., ten Dijke, P., Iwata, K. K., and Massague, J. (1990). Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J. Biol. Chem. 265, 20533-20538.
17. Cheng, L., Nagabhushan, M., Pretlow, T. P., Amini, S. B., and Pretlow, T. G. (1996). Expression of E-cadherin in primary and metastatic prostate cancer. Am. J. Pathol. 148, 1375-1380.
18. Cher., M. L., Bova, G. S., Moore, D. H., Small, E. J., Carroll, P. R., Pin, S. S., Epstein, J. I., Isaacs, W. B., and Jensen, R. H. (1996). Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 56, 3091-3102.
19. Ching, K. Z., Ramsey, E., Pettigrew, N., D'Cunha, R., Jason, M., and Dodd, J. G. (1993). Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol. Cell Biochem. 126, 151-158.
20. Chung, L. W. (1995). The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surv. 23, 33-42.
21. Chung, L. W., Li, W., Gleave, M. E., Hsieh, J. T., Wu, H. C., Sikes, R. A., Zhau, H. E., Bandyk, M. G., Logothetis, C. J., and Rubin, J. S. (1992). Human prostate cancer model: Roles of growth factors and extracellular matrices. J. Cell Biochem. Suppl. 99-105.
22. Coffey, D. S. (1996). Prostate cancer metastasis: Talking the walk [news; comment]. Nat. Med. 2, 1305-1306.
23. Cohen, M. M., Jr. (1994). Wiedemann-Beckwith syndrome, imprinting, IGF2, and H19: Implications for hemihyperplasia, associated neoplasms, and overgrowth [see comments]. Am. J. Med. Genet. 52, 233-234.
24. Cohen, P., Peehl, D. M., Lamson, G. and Rosenfeld, R. G. (1991). Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J. Clin. Endocrinol. Metab. 73, 401-407.
25. Coleman, C. N., and Kaplan, I. D. (1993). Prostate cancer. Technology versus biology [editorial]. Cancer 72, 305-309.
26. Colombel, M., Radvanyi, F., Blanche, M., Abbou, C., Buttyan, R., Donehower, L. A., Chopin, D., and Thiery, J. P. (1995). Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene 10, 1269-1274.
27. Condon, M. S. and Bosland, M. C. (1999). The role of stromal cells in prostate cancer development and progression [In Process Citation]. In Vivo 13, 61-65.
28. Connolly, J. M. and Rose, D. P. (1989). Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line. Prostate 15, 177-186.
29. Connolly, J. M., and Rose, D. P. (1998). Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice. J. Urol. 160, 932-936.
30. Coulson, J. M., Poyner, D. R., Chantry, A., Irwin, W. J., and Akhtar, S. (1996). A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells. Mol. Pharmacol. 50, 314-325.
31. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Hittmair, A., Zhang, J., Thurnher, M., Bartsch, G., and Klocker, H. (1996). Regulation of prostatic growth and function by peptide growth factors. Prostate 28, 392-405.
32. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., and Klocker, H. (1994). Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54, 5474-5478.
33. Cunha, G. R. (1985). Mesenchymal-epithelial interactions during androgen-induced development of the prostate. Prog. Clin. Biol. Res. 171, 15-24.
34. Cunha, G. R. (1994). Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 74, 1030-1044.
35. Cunha, G. R., and Lung, B. (1978). The possible influences of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice. J. Exp. Zool. 205, 181-194.
36. Cunha, G. R., Fujii, H., Neubauer, B. L., Shannon, J. M., Sawyer, L., and Reese, B. A. (1983). Epithelial-mesenchymal interactions in prostatic development. I. Morphological observation of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J. Cell. Biol. 96, 1662-1670.
37. Cunha, G. R., Donjacour, A. A., Cooke, P. S., Mee, S., Bigsby, R. M., Higgins, S. J., and Sugimura, Y. (1987). The endocrinology and developmental biology of the prostate. Endocr. Rev. 8, 338-362.
38. Cunha, G. R., Hayashi, N., and Wong, Y. C. (1991). Regulation of differentiation and growth of normal adult and neoplastic epithelia by inductive mesenchyme. Cancer Surv. 11, 73-90.
39. Cunha, G. R., Foster, B., Thomson, A., Sugimura, Y., Tanji, N., Tsuji, M., Terada, N., Finch, P. W., and Donjacour, A. A. (1995). Growth factors as mediators of androgen action during the development of the male urogenital tract. World J. Urol. 13, 264-276.
40. Cunha, G. R., Hayward, S. W., Dahiya, R., and Foster, B. A. (1996). Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anat. 155, 63-72.
41. Daughaday, W. H., and Rotwein, P. (1989). Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev. 10, 68-91.
42. Davies, D. E., and Chamberlin, S. G. (1996). Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem. Pharmacol. 51, 1101-1110.
43. Davies, P. and Eaton, C. L. (1989). Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate. Prostate 14, 123-132.
44. De Marzo, A. M., Knudsen, B., Chan-Tack, K., and Epstein, J. I. (1999). E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 53, 707-713.
45. Derynck, R. (1988). Transforming growth factor alpha. Cell 54, 593-595.
46. Derynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., and Berger, W. H. (1987). Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res. 47, 707-712.
47. Djakiew, D., Delsite, R., Pflug, B., Wrathall, J., Lynch, J. H., and Onoda, M. (1991). Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res. 51, 3304-3310.
48. Djakiew, D., Pflug, B., and Onoda, M. (1993). Stromal-epithelial paracrine interactions in the neoplastic rat and human prostate. Adv. Exp. Med. Biol. 330, 185-202.
49. Dong, J. T., Lamb, P. W., Rinker-Schaeffer, C. W., Vukanovic, J., Ichikawa, T., Isaacs, J. T., and Barrett, J. C. (1995). KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2 [see comments]. Science 268, 884-886.
50. Dong, J. T., Suzuki, H., Pin, S. S., Bova, G. S., Schalken, J. A., Isaacs, W. B., Barrett, J. C., and Isaacs, J. T. (1996). Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res. 56, 4387-4390.
51. Dong, J. T., Isaacs, W. B., and Isaacs, J. T. (1997). Molecular advances in prostate cancer. Curr. Opin. Oncol. 9, 101-107.
52. Donjacour, A. A., Thomson, A. A., and Cunha, G. R. (1998). Enlargement of the ampullary gland and seminal vesicle, but not the prostate in int-2/Fgf-3 transgenic mice. Differentiation 62, 227-237.
53. Dvorak, H. F., Sioussat, T. M., Brown, L. F., Berse, B., Nagy, J. A., Sotrel, A., Manseau, E. J., Van de Water, L., and Senger, D. R. (1991). Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J. Exp. Med. 174, 1275-1278.
54. Estham, J. A., Truong, L. D., Rogers, E., Kattan, M., Flanders, K. C., Scardino, P. T., and Thompson, T. C. (1995). Transforming growth factor-beta 1: Comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab. Invest. 73, 628-635.
55. Elson, S. D., Browne, C. A., and Thorburn, G. D. (1984). Identification of epidermal growth factor-like activity in human male reproductive tissues and fluids. J. Clin. Endocrinol. Metab. 58, 589-594.
56. Esch, F., Baird, A., Ling, N., Ueno, N., Hill, F., Denoroy, L., Klepper, R., Gospodarowicz, D., Bohlen, P., and Guillemin, R. (1985). Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc. Natl. Acad. Sci. USA 82, 6507-6511.
57. Ewing, C. M., Ru, N., Morton, R. A., Robinson, J. C., Wheelock, M. J., Johnson, K. R., Barrett, J. C., and Isaacs, W. B. (1995). Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: Correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res. 55, 4813-4817.
58. Finch, P. W., Cunha, G. R., Rubin, J. S., Wong, J., and Ron, D. (1995). Pattern of keratinocyte growth factor and keratinocyte growth factor receptor expression during mouse fetal development suggests a role in mediating morphogenetic mesenchymal-epithelial interactions. Dev. Dyn. 203, 223-240.
59. Fiorelli, G., De Bellis, A., Longo, A., Natali, A., Costantini, A., and Serio, M. (1989). Epidermal growth factor receptors in human hyperplastic prostate tissue and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. J. Clin. Endocrinol. Metab. 68, 740-743.
60. Fiorelli, G., De Bellis, A., Longo, A., Giannini, S., Natali, A., Costantini, A., Vannelli, G. B., and Serio, M. (1991). Insulin-like growth factor-I receptors in human hyperplastic prostate tissue. Characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. J. Clin. Endocrinol. Metab. 72, 740-746.
61. Fontana, A., Frei, K., Bodmer, S., Hofer, E., Schreier, M. H., Palladino, M. A., Jr., and Zinkernagel, R. M. (1989). Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J. Immunol. 143, 3230-3234.
62. Fontana, A., Constam, D. B., Frei, K., Malipiero, U., and Pfister, H. W. (1992). Modulation of the immune response by transforming growth factor beta. Int. Arch. Allergy Immunol. 99, 1-7.
63. Fowler, J. E., Jr., Lau, J. L., Ghosh, L., Mills, S. E., and Mounzer, A. (1988). Epidermal growth factor and prostatic carcinoma: an immunohistochemical study. J. Urol. 139, 857-861.
64. Freeman, M. R., Schneck, F. X., Gagnon, M. L., Corless, C., Soker, S., Niknejad, K., Peoples, G. E., and Klagsbrun, M. (1995). Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis. Cancer Res. 55, 4140-4145.
65. Fudge, K., Wang, C. Y., and Stearns, M. E. (1994). Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod. Pathol. 7, 549-554.
66. Fukunage, Y., Sobue, M., Suzaki, N., Kusida, H., and Suzuki, S. (1975). Synthesis of a fluoragenic mucopolysaccharide by chondrocytes in cell cultures with 4-methyl-umbelliferyl-β-D-xyloside. Biochem. Biophys. Acta 381, 443-447.
67. George, D. J., Suzuki, H., Bova, G. S., and Isaacs, J. T. (1998). Mutational analysis of the TrkA gene in prostate cancer. Prostate 36, 172-180.
68. Ghosh, A. K., Shankar, D. B., Shackleford, G. M., Wu, K., T'Ang, A., Miller, G. J., Zheng, J., and Roy-Burman, P. (1996). Molecular cloning and characterization of human FGF8 alternative messenger RNA forms. Cell Growth Differ. 7, 1425-1434.
69. Givol, D., and Yayon, A. (1992). Complexity of FGF receptors: Genetic basis for structural diversity and functional specificity. Faseb. J. 6, 3362-3369.
70. Gleason, P. E., Jones, J. A., Regan, J. S., Salvas, D. B., Eble, J. N., Lamph, W. W., Vlahos, C. J., Huang, W. L., Falcone, J. F., and Hirsch, K. S. (1993). Platelet derived growth factor (PDGF), androgens and inflammation: Possible etiologic factors in the development of prostatic hyperplasia. J. Urol. 149, 1586-1592.
71. Gleich, L. L., Srivastava, L., and Gluckman, J. L. (1996). Plasma platelet-derived growth factor: Preliminary study of a potential marker in head and neck cancer. Ann. Otol. Rhinol. Laryngol. 105, 710-712.
72. Glynne-Jones, E., Goddard, L., and Harper, M. E. (1996). Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum. Pathol. 27, 688-694.
73. Gold, J. S., Bao, L., Ghoussoub, R. A., Zetter, B. R., and Rimm, D. L. (1997). Localization and quantitation of expression of the cell motility-related protein thymosin beta 15 in human breast tissue. Mod. Pathol. 10, 1106-1112.
74. Graham, C. W., Lynch, J. H., and Djakiew, D. (1992). Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J. Urol. 147, 1444-1447.
75. Gregory, H., Willshire, I. R., Kavanagh, J. P., Blacklock, N. J., Chowdury, S., and Richards, R. C. (1986). Urogastrone-epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy. Clin. Sci. 70, 359-363.
76. Grossfeld, G. R., Hayward, S. W., Tlsty, T. D., and Cunha, G. R. (1998). The role of stroma in prostatic carcinogenesis. Endocrine-Related Cancer 5, 253-270.
77. Guidi, A. J., Abu-Jawdeh, G., Tognazzi, K., Dvorak, H. F., and Brown, L. F. (1996). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 78, 454-460.
78. Guo, Y., and Kyprianou, N. (1999). Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res. 59, 1366-1371.
79. Harper, M. E., Goddard, L., Glynne-Jones, E., Wilson, D. W., Price-Thomas, M., Peeling, W. B., and Griffiths, K. (1993). An immunocytochemical analysis of TGF alpha expression in benign and malignant prostatic tumors. Prostate 23, 9-23.
80. Hayashi, N., and Cunha, G. R. (1991). Mesenchyme-induced changes in the neoplastic characteristics of the Dunning prostatic adenocarcinoma. Cancer Res. 51, 4924-4930.
81. Hayashi, N., Cunha, G. R., and Wong, Y. C. (1990). Influence of male genital tract mesenchymes on differentiation of Dunning prostatic adenocarcinoma. Cancer Res. 50, 4747-4754.
82. Hayward, S. W., Dahiya, R., Cunha, G. R., Bartek, J., Deshpande, N., and Narayan, P. (1995). Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev. Biol. Anim. 31, 14-24.
83. Hayward, S. W., Cunha, G. R., and Dahiya, R. (1996). Normal development and carcinogenesis of the prostate. A unifying hypothesis. Ann. N.Y. Acad. Sci. 784, 50-62.
84. Hayward, S. W., Rosen, M. A., and Cunha, G. R. (1997). Stromal-epithelial interactions in the normal and neoplastic prostate. Br. J. Urol. 79 Suppl. 2, 18-26.
85. Hayward, S. W., Grossfeld, G. D., Tlsty, T. D., and Cunha, G. R. (1998a). Genetic and epigenetic influences in prostatic carcinogenesis (review). Int. J. Oncol. 13, 35-47.
86. Hayward, S. W., Haughney, P. C., Rosen, M. A., Greulich, K. M., Weier, H. U., Dahiya, R., and Cunha, G. R. (1998b). Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. Differentiation 63, 131-140.
87. He, B., Wang, Y. Z., and Wong, Y. C. (1996). Differential Expression of transforming growth factor-a (TGF-a) in dorsolateral (DLP) and ventral prostate (VP) during prostate carcinogenesis. Proc. Am. Assoc. Cancer Res. 37, 148.
88. He, W. W., Sciavolino, P. J., Wing, J., Augustus, M., Hudson, P., Meissner, P. S., Curtis, R. T., Shell, B. K., Bostwick, D. G., Tindall, D. J., Gelmann, E. P., Abate-Shen, C., and Carter, K. C. (1997). A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 43, 69-77.
89. Heidenberg, H. B., Sesterhenn, I. A., Gaddipati, J. P., Weghorst, C. M., Buzard, G. S., Moul, J. W., and Srivastava, S. (1995). Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 154, 414-421.
90. Helting, T., and Roden, L. (1969). Biosynthesis of chondroitin sulphate. I. Galactosyl transfer in the formation of the carbohydrate-protein linkage region. J. Biol. Chem. 244, 2790-2798.
91. Hierowski, M. T., McDonald, M. W., Dunn, L., and Sullivan, J. W. (1987). The partial dependency of human prostatic growth factor on steroid hormones in stimulating thymidine incorporation into DNA. J. Urol. 138, 909-912.
92. Hiramatsu, M., Kashimata, M., Minami, N., Sato, A., and Murayama, M. (1988). Androgenic regulation of epidermal growth factor in the mouse ventral prostate. Biochem. Int. 17, 311-317.
93. Hirata, Y., Uchihashi, M., Hazama, M., and Fujita, T. (1987). Epidermal growth factor in human seminal plasma. Horm. Metab. Res. 19, 35-37.
94. Hofer, D. R., Sherwood, E. R., Bromberg, W. D., Mendelsohn, J., Lee, C., and Kozlowski, J. M. (1991). Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res. 51, 2780-2785.
95. Hu, Z., Evarts, R. P., Fujio, K., Omori, N., Omori, M., Marsden, E. R., and Thorgeirsson, S. S. (1996). Expression of transforming growth factor alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met and acidic fibroblast growth factor/fibroblast growth factor receptors during hepatocarcinogenesis. Carcinogenesis 17, 931-938.
96. Huggins, C., and Hodges, C. V. (1941). Studies of prostatic cancer: 1. Effect of castration, oestrogen and androgen injections on serum phosphates in metastatic carcinoma of the prostate. Cancer Res. 1, 293-297.
97. Humphrey, P. A., Zhu, X., Zarnegar, R., Swanson, P. E., Ratliff, T. L., Vollmer, R. T., and Day, M. L. (1995). Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol. 147, 386-396.
98. Huncharek, M., and Muscat, J. (1995). Genetic characteristics of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 4, 681-687.
99. Hyder, S. M., Stancel, G. M., Chiappetta, C., Murthy, L., Boettger-Tong, H. L., and Makela, S. (1996). Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res. 56, 3954-3960.
100. Ikeda, T., Lioubin, M. N., and Marquardt, H. (1987). Human transforming growth factor type beta 2: Production by a prostatic adenocarcinoma cell line, purification, and initial characterization. Biochemistry 26, 2406-2410.
101. Isaacs, W. B. (1995). Molecular genetics of prostate cancer. Cancer Surv. 25, 357-379.
102. Isaacs, W. B., Carter, B. S., and Ewing, C. M. (1991). Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 51, 4716-4720.
103. Ittmann, M. M. (1998). Chromosome 10 alterations in prostate adenocarcinoma (review). Oncol. Rep. 5, 1329-1335.
104. Ittmann, M. M., and Wieczorek, R. (1996). Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum. Pathol. 27, 28-34.
105. Iwamura, M., Sluss, P. M., Casamento, J. B., and Cockett, A. T. (1993). Insulin-like growth factor 1: Action and receptor characterization in human prostate cancer cell lines. Prostate 22, 243-252.
106. Iwamura, M., di Sant'agnese, P. A., Wu, G., Benning, C. M., Cockett, A. T., and Gershagen, S. (1994). Overexpression of human epidermal growth factor receptor and c-erbB-2 by neuroendocrine cells in normal prostatic tissue. Urology 43, 838-843.
107. Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., and Weinberg, R. A. (1992). Effects of an Rb mutation in the mouse [see comments]. Nature 359, 295-300.
108. Jackson, M. W., Bentel, J. M., and Tilley, W. D. (1997). Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J. Urol. 157, 2323-2328.
109. Jacobs, S. C., and Story, M. T. (1988). Exocrine secretion of epidermal growth factor by the rat prostate: Effect of adrenergic agents, cholinergic agents, and vasoactive intestinal peptide. Prostate 13, 79-87.
110. Jakowlew, S. B., Dillard, P. J., Kondaiah, P., Sporn, M. B., and Roberts, A. B. (1988). Complimentary deoxyribonucleic acid cloning of a novel transforming growth factor-β mesenger ribonucleic acid from chick embryo chondrocytes. Mol. Endocrinol. 2, 747-755.
111. Kaicer, E. K., Blat, C., and Harel, L. (1991). IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. Growth Factors 4, 231-237.
112. Kan, M., Huang, J. S., Mansson, P. E., Yasumitsu, H., Carr, B., and McKeehan, W. L. (1989). Heparin-binding growth factor type 1 (acidic fibroblast growth factor): A potential biphasic autocrine and paracrine regulator of hepatocyte regeneration. Proc. Natl. Acad. Sci. USA 86, 7432-7436.
113. Kan, M., Yan, G. C., Xu, J., Nakahara, M., and Hou, J. (1992). Receptor phenotype underlies differential response of hepatocytes and nonparenchymal cells to heparin-binding fibroblast growth factor type 1 (aFGF) and type 2 (bFGF). In Vitro Cell Dev. Biol. 28A, 515-520.
114. Kaplan, P. J., Mohan, S., Cohen, P., Foster, B. A., and Greenberg, N. M. (1999). The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res. 59, 2203-2209.
115. Kim, J. H., Sherwood, E. R., Sutkowski, D. M., Lee, C., and Kozlowski, J. M. (1991). Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. J. Urol. 146, 171-176.
116. Kim, I. Y., Ahn, H. J., Zelner, D. J., Park, L., Sensibar, J. A., and Lee, C. (1996a). Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression. Mol. Endocrinol. 10, 107-115.
117. Kim, I. Y., Ahn, H. J., Zelner, D. J., Shaw, J. W., Lang, S., Kato, M., Oefelein, M. G., Miyazono, K., Nemeth, J. A., Kozlowski, J. M., and Lee, C. (1996b). Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin. Cancer Res. 2, 1255-1261.
118. Kingsley, D. M. (1994). The TGF-beta superfamily: New members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 8, 133-146.
119. Kishi, H., Ishibe, T., Usui, T., and Miyachi, Y. (1988). Epidermal growth factor (EGF) in seminal plasma and prostatic gland: A radioreceptor assay. Arch. Androl. 20, 243-249.
120. Kondaiah, P., Sands, M. J., Smith, J. M., Fields, A., Roberts, A. B., Sporn, M. B., and Melton, D. A. (1990). Identification of a novel transforming growth factor-β (TGF-β5) mRNA in Xenopus laevis. J. Biol. Chem. 265, 1089-1093.
121. Konishi, N., Cho, M., Yamamoto, K., and Hiasa, Y. (1997). Genetic changes in prostate cancer. Pathol. Int. 47, 735-747.
122. Kubota, Y., Fujinami, K., Uemura, H., Dobashi, Y., Miyamoto, H., Iwasaki, Y., Kitamura, H., and Shuin, T. (1995). Retinoblastoma gene mutations in primary human prostate cancer. Prostate 27, 314-320.
123. Kunimi, K., Amano, T., and Uchibayashi, T. (1996). Point mutation of the p53 gene is an infrequent event in untreated prostate cancer. Cancer Detect. Prev. 20, 218-222.
124. Kyprianou, N., and Isaacs, J. T. (1989). Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol. Endocrinol. 3, 1515-1522.
125. Lee, C. S., Redshaw, A., and Boag, G. (1996). TGF-alpha immunoreactivity in laryngeal carcinoma: Lack of prognostic value and correlation to EGF-receptor expression. Aust. N. Z. J. Surg. 66, 464-468.
126. Lee, C., Sintich, S. M., Mathews, E. P., Shah, A. H., Kundu, S. D., Perry, K. T., Cho, J. S., Ilio, K. Y., Cronauer, M. V., Janulis, L., and Sensibar, J. A. (1999). Transforming growth factor-beta in benign and malignant prostate. Prostate 39, 285-290.
127. Lindahl, F. C., and Roden, L. (1966). The chondroitin sulphate-protein linkage. J. Biol. Chem. 241, 2113-2119.
128. Lopez-Casillas, F., Cheifetz, S., Doody, J., Andres, J. L., Lane, W. S., and Massague, J. (1991). Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 67, 785-795.
129. Lopez-Casillas, F., Wrana, J. L., and Massague, J. (1993). Betaglycan presents ligand to the TGF beta signaling receptor. Cell 73, 1435-1444.
130. Lu, W., Luo, Y., Kan, M., and McKeehan, W. L. (1999). Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate [In Process Citation]. J. Biol. Chem. 274, 12827-12834.
131. Lu, X. F., Tam, N. N. C., and Wong, Y. C. (2000). The roles of growth factors in mediating mesenchymal influence on the cytodifferentiation of the Dunning prostatic adenocarcinoma. Tumor Biol. 21, 21-32.
132. Lubrano, C., Petrangeli, E., Catizone, A., Santonati, A., Concolino, G., Rombola, N., Frati, L., Di Silverio, F., and Sciarra, F. (1989). Epidermal growth factor binding and steroid receptor content in human benign prostatic hyperplasia. J. Steroid Biochem. 34, 499-504.
133. MacDonald, A., and Habib, F. K. (1992). Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br. J. Cancer 65, 177-182.
134. MacGrogan, D., Saint-Andre, J. P., and Dicou, E. (1992). Expression of nerve growth factor and nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines. J. Neurochem. 59, 1381-1391.
135. Maddy, S. Q., Chisholm, G. D., Hawkins, R. A., and Habib, F. K. (1987). Localization of epidermal growth factor receptors in the human prostate by biochemical and immunocytochemical methods. J. Endocrinol. 113, 147-153.
136. Maddy, S. Q., Chisholm, G. D., Busuttil, A., and Habib, F. K. (1989). Epidermal growth factor receptors in human prostate cancer: correlation with histological differentiation of the tumour. Br. J. Cancer 60, 41-44.
137. Mansson, P. E., Adams, P., Kan, and McKeeham, W. L. (1989). HBGF gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors. Cancer Res. 49, 2485-2494.
138. Mariotti, A., Thornton, M., and Mawhinney, M. (1981). Actions of androgen and estrogen on collagen level in the male accessory sex organs. Endocrinology 109, 837-843.
139. Mariotti, A., Donovan, M. P., and Mawhinney, M. (1982). Collagen and cellular proliferation in spontaneous canine prostatic hypertrophy. J. Urol. 127, 795-797.
140. Mariotti, A., and Mawhinney, M. (1981). Hormonal control of accessory sex organ fibromuscular stroma. Prostate 2, 397-408.
141. Martikainen, P., Kyprianou, N., and Isaacs, J. T. (1990). Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology 127, 2963-2968.
142. Martinez-Lacaci, I., and Dickson, R. B. (1996). Dual regulation of the epidermal growth factor family of growth factors in breast cancer by sex steroids and protein kinase C. J. Steroid Biochem. Mol. Biol. 57, 1-11.
143. Marx, J. (1995). New clue to prostate cancer spread [news; comment]. Science 268, 799-800.
144. Massague, J. (1987). The TGF-beta family of growth and differentiation factors. Cell 49, 437-438.
145. Massague, J., Cheifetz, S., Boyd, F. T., and Andres, J. L. (1990). TGF-beta receptors and TGF-beta binding proteoglycans: recent progress in identifying their functional properties. Ann. N.Y. Acad. Sci. 593, 59-72.
146. Matsumoto, K., Date, K., Shimura, H., and Nakamura, T. (1996). Acquisition of invasive phenotype in gallbladder cancer cells via mutual interaction of stromal fibroblasts and cancer cells as mediated by hepatocyte growth factor. Jpn. J. Cancer Res. 87, 702-710.
147. Matuo, Y., Nishi, N., Tanaka, H., Sasaki, I., Isaacs, J. T., and Wada, F. (1988). Production of IGF-II-related peptide by an anaplastic cell line (AT-3) established from the Dunning prostatic carcinoma of rats. In Vitro Cell Dev. Biol. 24, 1053-1056.
148. Matuo, Y., Nishi, N., Takasuka, H., Masuda, Y., Nishikawa, K., Isaacs, J. T., Adams, P. S., McKeehan, W. L., and Sato, G. H. (1990). Production and significance of TGF-beta in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma. Biochem. Biophys. Res. Commun. 166, 840-847.
149. McKeehan, W. L., and Adams, P. S. (1988). Heparin-binding growth factor/prostatropin attenuates inhibition of rat prostate tumor epithelial cell growth by transforming growth factor type beta. In Vitro Cell Dev. Biol. 24, 243-246.
150. McKeehan, W. L., Adams, P. S., and Rosser, M. P. (1984). Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res. 44, 1998-2010.
151. McKeehan, W. L., Adams, P. S., and Fast, D. (1987). Different hormonal requirements for androgen-independent growth of normal and tumor epithelial cells from rat prostate. In Vitro Cell Dev. Biol. 23, 147-152.
152. Merz, V. W., Miller, G. J., Krebs, T., Timme, T. L., Kadmon, D., Park, S. H., Egawa, S., Scardino, P. T., and Thompson, T. C. (1991). Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: Evidence for a paracrine role during progression. Mol. Endocrinol. 5, 503-513.
153. Meyers, F. J., Gumerlock, P. H., Chi, S. G., Borchers, H., Deitch, A. D., and de Vere White, R. W. (1998). Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 83, 2534-2539.
154. Miki, T., Bottaro, D. P., Fleming, T. P., Smith, C. L., Burgess, W. H., Chan, A. M., and Aaronson, S. A. (1992). Determination of ligand-binding specificity by alternative splicing: Two distinct growth factor receptors encoded by a single gene. Proc. Natl. Acad. Sci. USA 89, 246-250.
155. Mise, M., Arii, S., Higashituji, H., Furutani, M., Niwano, M., Harada, T., Ishigami, S., Toda, Y., Nakayama, H., Fukumoto, M., Fujita, J., and Imamura, M. (1996). Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23, 455-464.
156. Mori, H., Maki, M., Oishi, K., Jaye, M., Igarashi, K., Yoshida, O., and Hatanaka, M. (1990). Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia. Prostate 16, 71-80.
157. Morton, R. A., Jr., and Isaacs, W. B. (1998). Molecular genetics of prostate cancer: Clinical applications. J. Natl. Med. Assoc. 90, S728-S731.
158. Muntzing, J. (1980). Androgen and collagen as growth regulators of the rat ventral prostate. Prostate 1, 71-78.
159. Mydlo, J. H., Michaeli, J., Heston, W. D., and Fair, W. R. (1988). Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma. Prostate 13, 241-247.
160. Myers, R. B., Kudlow, J. E., and Grizzle, W. E. (1993). Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia. Mod. Pathol. 6, 733-737.
161. Navone, N. M., Labate, M. E., Troncoso, P., Pisters, L. L., Conti, C. J., von Eschenbach, A. C., and Logothetis, C. J. (1999). p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastic potential. J. Urol. 161, 304-308.
162. Nemeth, J. A., Sensibar, J. A., White, R. R., Zelner, D. J., Kim, I. Y., and Lee, C. (1997). Prostatic ductal system in rats: Tissue-specific expression and regional variation in stromal distribution of transforming growth factor-β1. Prostate 33, 64-71.
163. Nilsen-Hamilton, M. (1990). Transforming growth factor-beta and its actions on cellular growth and differentiation. Curr. Top. Dev. Biol. 24, 95-136.
164. Nishi, N., Matuo, Y., Nakamoto, T., and Wada, F. (1988). Proliferation of epithelial cells derived from rat dorsolateral prostate in serum-free primary cell culture and their response to androgen. In Vitro Cell Dev. Biol. 24, 778-786.
165. Noble, R. L. (1980). Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen. Cancer Res. 40, 3547-3550.
166. Ogata, Y., Harada, Y., Fujii, T., Yamana, H., Fujita, H., and Shirouzu, K. (1996). Immunohistochemical localization of vascular endothelial growth factor in esophageal cancer. Kurume Med. J. 43, 157-163.
167. Okayama, M., Kimata, K., and Suzuki, S. (1973). The inflkuence of p-nitrophenye-β-D-xyloside on the synthesis of proteochondroitin sulfate by slices of embryonic chick cartilage. J. Biochem. 74, 1069-1073.
168. Paul, A., and Habib, F. (1998). Low-affinity nerve growth factor receptors (p75LNGFR) in human prostate tissue: Stromal localisation. Urol. Res. 26, 111-116.
169. Peehl, D. M., and Sellers, R. G. (1998). Basic FGF, EGF, and PDGF modify TGFbeta-induction of smooth muscle cell phenotype in human prostatic stromal cells. Prostate 35, 125-134.
170. Peehl, D. M., and Stamey, T. A. (1986). Growth responses of normal, benign hyperplastic, and malignant human prostatic epithelial cells in vitro to cholera toxin, pituitary extract, and hydrocortisone. Prostate 8, 51-61.
171. Pepper, M. S., Belin, D., Montesano, R., Orci, L., and Vassalli, J. D. (1990). Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J. Cell Biol. 111, 743-755.
172. Pietrzkowski, Z., Mulholland, G., Gomella, L., Jameson, B. A., Wernicke, D., and Baserga, R. (1993). Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 53, 1102-1106.
173. Pisters, L. L., Troncoso, P., Zhau, H. E., Li, W., von Eschenbach, A. C., and Chung, L. W. (1995). c-met proto-oncogene expression in benign and malignant human prostate tissues. J. Urol. 154, 293-298.
174. Pollard, M., and Pluckert, P. H. (1987). Autochthonous prostate adenocarcinomas in Lobund-Wistar rats: A model system. Prostate 11, 219-227.
175. Potapova, O., Fakhrai, H., and Mercola, D. (1996). Growth factor PDGF-B/v-sis confers a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells devoid of receptors: Evidence for an autocrine, but not a paracrine, mechanism. Int. J. Cancer 66, 669-677.
176. Roden, L. (1980). Structure and metabolism of connective tissue proteoglycans. 1980. In "The Biochemistry of glycoproteins and proteoglycans" (W. J. Lennarz, ed.), pp. 267-371. Plenum, New York.
177. Ruan, W., Powell-Braxton, L., Kopchick, J. J., and Kleinberg, D. L. (1999). Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 140, 1984-1989.
178. Rubin, S. J., Hallahan, D. E., Ashman, C. R., Brachman, D. G., Beckett, M. A., Virudachalam, S., Yandell, D. W., and Weichselbaum, R. R. (1991). Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J. Surg. Oncol. 46, 31-36.
179. Rubin, J. S., Bottaro, D. P., Chedid, M., Miki, T., Ron, D., Cunha, G. R., and Finch, P. W. (1995). Keratinocyte growth factor as a cytokine that mediates mesenchymal-epithelial interaction. Exs 74, 191-214.
180. Saksela, O., Moscatelli, D., Sommer, A., and Rifkin, D. B. (1988). Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J. Cell. Biol. 107, 743-751.
181. Sandgren, E. P., Luetteke, N. C., Palmiter, R. D., Brinster, R. L., and Lee, D. C. (1990). Overexpression of TGF alpha in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61, 1121-1135.
182. Sankar, S., Mahooti-Brooks, N., Centrella, M., McCarthy, T. L., and Madri, J. A. (1995). Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J. Biol. Chem. 270, 13567-13572.
183. Santti, R., Newbold, R. R., Makela, S., Pylkkanen, L., and McLachlan, J. A. (1994). Developmental estrogenization and prostatic neoplasia. Prostate 24, 67-78.
184. Sattler, H. P., Rohde, V., Bonkhoff, H., Zwergel, T., and Wullich, B. (1999). Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer [In Process Citation]. Prostate 39, 79-86.
185. Schmitt, J. F., Hearn, M. T., and Risbridger, G. P. (1996). Expression of fibroblast growth factor-8 in adult rat tissues and human prostate carcinoma cells. J. Steroid Biochem. Mol. Biol. 57, 173-178.
186. Schroeder, W., Biesterfeld, S., Zillessen, S., and Rath, W. (1997). Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res. 17, 2799-2802.
187. Schuurmans, A. L., Bolt, J., and Mulder, E. (1988). Androgens and transforming growth factor beta modulate the growth response to epidermal growth factor in human prostatic tumor cells (LNCaP). Mol. Cell Endocrinol. 60, 101-104.
188. Shaikh, N., Lai, L., McLoughlin, J., Clark, D., and Williams, G. (1990). Quantitative analysis of epidermal growth factor in human benign prostatic hyperplasia and prostatic carcinoma and its prognostic significance. Anticancer Res. 10, 873-874.
189. Shain, S. A., Lin, A. L., Koger, J. D., and Karaganis, A. G. (1990). Rat prostate cancer cells contain functional receptors for transforming growth factor-beta. Endocrinology 126, 818-825.
190. Sherwood, E. R., and Lee, C. (1995). Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. World J. Urol. 13, 290-296.
191. Shikata, H., Utsumi, N., Hiramatsu, M., Minami, N., Nemoto, N., and Shikata, T. (1984). Immunohistochemical localization of nerve growth factor and epidermal growth factor in guinea pig prostate gland. Histochemistry 80, 411-413.
192. Shima, H., Tsuji, M., Elfman, F., and Cunha, G. R. (1995). Development of male urogenital epithelia elicited by soluble mesenchymal factors. J. Androl. 16, 233-241.
193. Sigala, S., Faraoni, I., Botticini, D., Paez-Pereda, M., Missale, C., Bonmassar, E., and Spano, P. (1999). Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell line [In Process Citation]. Clin. Cancer Res. 5, 1211-1218.
194. Sinowatz, F., Amselgruber, W., Lincoln, D., Sasse, J., Kolle, S., Plendl, J., and Kayser, K. (1995). Role of basic fibroblast growth factor in prostatic tumors. Nutrition 11, 619-621.
195. Sitaras, N. M., Sariban, E., Bravo, M., Pantazis, P., and Antoniades, H. N. (1988). Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res. 48, 1930-1935.
196. Srivastava, S., Katayose, D., Tong, Y. A., Craig, C. R., McLeod, D. G., Moul, J. W., Cowan, K. H., and Seth, P. (1995). Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. Urology 46, 843-848.
197. Steiner, M. S. (1993). Role of peptide growth factors in the prostate: a review. Urology 42, 99-110.
198. Steiner, M. S., and Barrack, E. R. (1992). Transforming growth factor-beta 1 overproduction in prostate cancer: Effects on growth in vivo and in vitro. Mol. Endocrinol. 6, 15-25.
199. Steiner, M. S., Zhou, Z. Z., Tonb, D. C., and Barrack, E. R. (1994). Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology 135, 2240-2247.
200. Stone, N. N., Fair, W. R., and Fishman, J. (1986). Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia. Prostate 9, 311-318.
201. Story, M. T. (1991). Polypeptide modulators of prostatic growth and development. Cancer Surv. 11, 123-146.
202. Story, M. T. (1995). Regulation of prostate growth by fibroblast growth factors. World J. Urol. 13, 297-305.
203. Story, M. T., Sasse, J., Jacobs, S. C., and Lawson, R. K. (1987). Prostatic growth factor: Purification and structural relationship to basic fibroblast growth factor. Biochemistry 26, 3843-3849.
204. Story, M. T., Livingston, B., Baeten, L., Swartz, S. J., Jacobs, S. C., Begun, F. P., and Lawson, R. K. (1989). Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor. Prostate 15, 355-365.
205. Suzuki, K., Hayashi, N., Miyamoto, Y., Yamamoto, M., Ohkawa, K., Ito, Y., Sasaki, Y., Yamaguchi, Y., Nakase, H., Noda, K., Enomoto, N., Arai, K., Yamada, Y., Yoshihara, H., Tujimura, T., Kawano, K., Yoshikawa, K., and Kamada, T. (1996). Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 56, 3004-3009.
206. Suzuki, H., Freije, D., Nusskern, D. R., Okami, K., Cairns, P., Sidransky, D., Isaacs, W. B., and Bova, G. S. (1998). Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58, 204-209.
207. Takano, S., Yoshii, Y., Kondo, S., Suzuki, H., Maruno, T., Shirai, S., and Nose, T. (1996). Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 56, 2185-2190.
208. Tam, N. N. C., and Wong, Y. C. (1999). Expression of vascular endothelial growth factor (VEGF) and its receptors flt-1 and flk-1 in sex hormone-induced prostatic carcinoma. Proc. AACR 40, 458.
209. Tam, N. N. C., Wang, Y. Z., and Wong, Y. C. (1997). The influcence of mesenchyme of neonatal seminal vesicle and embroyonic urogenital sinus on the morphologic and functional cytodifferentiation of Dunning prostatic adenocarcinoma: Roles of growth factors and proto-oncogenes. Urol. Oncol. 3, 85-93.
210. Taylor, T. B., and Ramsdell, J. S. (1993). Transforming growth factor-alpha and its receptor are expressed in the epithelium of the rat prostate gland. Endocrinology 133, 1306-1311.
211. Tennant, M. K., Thrasher, J. B., Twomey, P. A., Birnbaum, R. S., and Plymate, S. R. (1996a). Insulin-like growth factor-binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization. J. Clin. Endocrinol. Metab. 81, 3783-3792.
212. Tennant, M. K., Thrasher, J. B., Twomey, P. A., Drivdahl, R. H., Birnbaum, R. S., and Plymate, S. R. (1996b). Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium J. Clin. Endocrinol. Metab. 81, 3774-3782.
213. Tenniswood, M. (1986). Role of epithelial-stromal interactions in the control of gene expression in the prostate: An hypothesis. Prostate 9, 375-385.
214. Thompson, T. C. (1990). Growth factors and oncogenes in prostate cancer. Cancer Cells 2, 345-354.
215. Thompson, T. C., Cunha, G. R., Shannon, J. M., and Chung, L. W. (1986). Androgen-induced biochemical responses in epithelium lacking androgen receptors: Characterization of androgen receptors in the mesenchymal derivative of urogenital sinus. J. Steroid Biochem. 25, 627-634.
216. Thompson, T. C., Southgate, J., Kitchener, G., and Land, H. (1989). Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56, 917-930.
217. Thompson, T. C., Truong, L. D., Timme, T. L., Kadmon, D., McCune, B. K., Flanders, K. C., Scardino, P. T., and Park, S. H. (1992). Transforming growth factor beta 1 as a biomarker for prostate cancer. J. Cell Biochem. Suppl. 54-61.
218. Thompson, T. C., Truong, L. D., Timme, T. L., Kadmon, D., McCune, B. K., Flanders, K. C., Scardino, P. T., and Park, S. H. (1993). Transgenic models for the study of prostate cancer. Cancer 71, 1165-1171.
219. Thrasher, J. B., Tennant, M. K., Twomey, P. A., Wettlaufer, J. N., and Plymate, S. R. (1996). Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: Clinical correlations. J. Urol. 155, 999-1003.
220. Timme, T. L., Yang, G., Truong, L. D., Kadmon, D., Park, S. H., and Thompson, T. C. (1995). Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World J. Urol. 13, 324-328.
221. Torre-Amione, G., Beauchamp, R. D., Koeppen, H., Park, B. H., Schreiber, H., Moses, H. L., and Rowley, D. A. (1990). A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 87, 1486-1490.
222. Traish, A. M., and Wotiz, H. H. (1987). Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology 121, 1461-1467.
223. Truong, L. D., Kadmon, D., McCune, B. K., Flanders, K. C., Scardino, P. T., and Thompson, T. C. (1993). Association of transforming growth factor-beta 1 with prostate cancer: An immunohistochemical study. Hum. Pathol. 24, 4-9.
224. Tsuji, M., Shima, H., Terada, N., and Cunha, G. R. (1994). 5 alpha-reductase activity in developing urogenital tracts of fetal and neonatal male mice. Endocrinology 134, 2198-2205.
225. Tsuka, H., Mori, H., Li, B., Kanamaru, H., Matsukawa, S., and Okada, K. (1998). Expression of c-MET/HGF receptor mRNA and protein in human non-malignant and malignant prostate tissues. Int. J. Oncol. 13, 927-934.
226. Umbas, R., Schalken, J. A., Aalders, T. W., Carter, B. S., Karthaus, H. F., Schaafsma, H. E., Debruyne, F. M., and Isaacs, W. B. (1992). Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 52, 5104-5109.
227. Umbas, R., Isaacs, W. B., Bringuier, P. P., Schaafsma, H. E., Karthaus, H. F., Oosterhof, G. O., Debruyne, F. M., and Schalken, J. A. (1994). Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 54, 3929-3933.
228. Visakorpi, T. (1999). Molecular genetics of prostate cancer [In Process Citation]. Ann. Chir. Gynaecol. 88, 11-16.
229. Vlahos, C. J., Kriauciunas, T. D., Gleason, P. E., Jones, J. A., Eble, J. N., Salvas, D., Falcone, J. F., and Hirsch, K. S. (1993). Platelet-derived growth factor induces proliferation of hyperplastic human prostatic stromal cells. J. Cell Biochem. 52, 404-413.
230. Wakui, S., Furusato, M., Sasaki, S., Masaoka, T., Ushigome, S., and Aizawa, S. (1996). Immunohistochemical localization of the epidermal growth factor-receptor in rhesus-monkey prostate. Anat. Histol. Embryol. 25, 109-111.
231. Wang, Y. Z., and Wong, Y. C. (1997). Oncogenes and tumor suppressor genes in prostate cancer: A review. Urol. Oncol. 3, 41-46.
232. Wang, Y. Z., and Wong, Y. C. (1998). Sex hormone-induced prostatic carcinogenesis in the noble rat: The role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 35, 165-177.
233. Weber, C. E. (1997). Molecular carcinogenesis of prostate cancer: Potential clinical relevance and nursing implications. Semin. Oncol. Nurs. 13, 99-107.
234. Wei, M. H., Popescu, N. C., Lerman, M. I., Merrill, M. J., and Zimonjic, D. B. (1996). Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Hum. Genet. 97, 794-797.
235. Whang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. W., Isaacs, W. B., and Sawyers, C. L. (1998). Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA 95, 5246-5250.
236. Wilding, G. (1991). Response of prostate cancer cells to peptide growth factors: Transforming growth factor-beta. Cancer Surv. 11, 147-163.
237. Wilding, G., Valverius, E., Knabbe, C., and Gelmann, E. P. (1989). Role of transforming growth factor-alpha in human prostate cancer cell growth. Prostate 15, 1-12.
238. Wong, Y. C., and Chan, F. L. (1993a). Effects of cis-4-hydroxy-L-proline on the androgen-induced growth of the lateral prostate of the prepubertally castrated guinea pig. Prostate 23, 337-354.
239. Wong, Y. C., and Chan, F. L. (1993b). Effects of p-nitrophenyl-β-D-xylopyranoside (β-D-xyloside) on the androgen-induced growth of the lateral prostate on the prepubertally castrated guinea pig. Prostate 23, 37-59.
240. Wong, Y. C., Cunha, G. R., and Hayashi, N. (1992). Effects of mesenchyme of the embryonic urogenital sinus and neonatal seminal vesicle on the cytodifferentiation of the Dunning tumor: Ultrastructural study. Acta Anat. 143, 139-150.
241. Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., and Massague, J. (1994). Mechanism of activation of the TGF-beta receptor. Nature 370, 341-347.
242. Wright, J. A., Turley, E. A., and Greenberg, A. H. (1993). Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy. Crit. Rev. Oncog. 4, 473-492.
243. Wu, H. H., Kawamata, H., Kawai, K., Lee, C., and Oyasu, R. (1993). Immunohistochemical localization of epidermal growth factor and transforming growth factor alpha in the male rat accessory sex organs. J. Urol. 150, 990-993.
244. Xie, B., Tsao, S. W., and Wong, Y. C. (1999a). Sex hormone-induced mammary carcinogenesis in female Noble rats: The role of androgens. Carcinogenesis 20, 1597-1606.
245. Xie, B., Tsao, S. W., and Wong, Y. C. (1999b). Sex hormone-induced mammary carcinogenesis in the female Noble rats: Expression of TGF-β1 and its receptors, TGF-α, and EGF-R in mammary carcinogenesis. Breast Cancer Res. Treat. In Press.
246. Xie, B., Tam, N. C., Tsao, S. W., and Wong, Y. C. (1999c). Coexpression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat. Br. J. Cancer 81, 1335-1343.
247. Yamasaki, L., Bronson, R., Williams, B. O., Dyson, N. J., Harlow, E., and Jacks, T. (1998). Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-) mice. Nat. Genet. 18, 360-364.
248. Yan, G., Fukabori, Y., McBride, G., Nikolaropolous, S., and McKeehan, W. L. (1993). Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol. Cell Biol. 13, 4513-4522.
249. Yang, E. Y., and Moses, H. L. (1990). Transforming growth factor beat 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J. Cell Biol. 111, 731-741.
250. Yang, C., Cirielli, C., Capogrossi, M. C., and Passaniti, A. (1995). Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res. 55, 4210-4213.
251. Yoshiji, H., Gomez, D. E., Shibuya, M., and Thorgeirsson, U. P. (1996). Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 56, 2013-2016.